-
The news of layoffs in the pharmaceutical industry continues, but CXO companies are aggressively "recruiting"
Time of Update: 2022-05-10
According to statistics, as of April 19, the 2021 annual reports disclosed by nearly 200 domestic listed pharmaceutical companies showed that the total number of employees of about 50 companies appeared.
-
Attacking innovative drugs, a large number of pharmaceutical companies have gained a lot
Time of Update: 2022-05-10
On April 19, the CDE website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
-
This month, more than 10 executives of pharmaceutical companies have resigned!
Time of Update: 2022-05-10
On April 12, Hengrui Pharmaceutical announced that the board of directors of the company has recently received a resignation report from Zou Jianjun, the company's deputy general manager.
-
Pharmaceutical companies promote digital development, which has become the general trend in the industry
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] In recent years, the state has begun to further meet the people's needs for convenient medical services by vigorously supporting the innovation of the "Internet +" medical service model .
-
It is difficult to develop new drugs, and a large number of drugs end in clinical failure
Time of Update: 2022-05-10
Some industry insiders who have been engaged in new drug research and development for many years said that there are five main reasons for the failure of the management of new drug research and development projects they participated in, including project approval mistakes, lack of project-matching stakeholders, uncertainty in technical risks, and late R&D application progress.
-
49 listed companies disclosed their 2022 first quarter reports, including 5 pharmaceutical companies including Keqian Bio and Chengda Pharmaceutical
Time of Update: 2022-05-10
05% year-on-year According to the performance report of Xiangsheng Medical for the first quarter of 2022, from January 1, 2022 to March 31, 2022, the company achieved an operating income of 100 million yuan, a year-on-year increase of 23.
-
In order to speed up the "return of blood", many pharmaceutical companies started the "selling, selling and selling" model during the year
Time of Update: 2022-05-10
[Pharmaceutical Network Industry News] Sihuan Pharmaceutical announced on the evening of April 18 that Hainan Sihuan Pharmaceutical, a wholly-owned subsidiary of the company, plans to sell the entire issued share capital of Beijing Xuansheng for 118 million yuan, and the net proceeds from the sale will be used for the group general working capital .
-
The centralized procurement of Chinese patent medicines is accelerating, and a large number of drugs will be reduced in prices in many places
Time of Update: 2022-05-09
[Pharmaceutical Network Industry News] The National Medical Insurance Bureau has recently made a unified deployment and coordination of the centralized procurement of local alliances, and has clarified that by the end of 2022, provinces (including inter-provincial alliances) will carry out their own centralized procurement of no less than 100 drug varieties.
-
Under the new situation, traditional Chinese medicine enterprises cooperate and win-win to help the high-quality development of traditional Chinese medicine hospitals
Time of Update: 2022-05-09
[Pharmaceutical Network Industry News] Recently, Wuhu Traditional Chinese Medicine Hospital and Ningbo Ninth Hospital have successively issued tender announcements, clarifying that while supplying Chinese medicine pieces, the company must provide supporting facilities including smart Chinese medicine pharmacies to help the hospital.
-
In the first half of 2022, pharmaceutical companies "group together" become the norm
Time of Update: 2022-05-09
Wanfu Bio & General Technology China Pharmaceutical: Signed a Strategic Cooperation Agreement on Antigen Detection Reagent Products On April 1, General Technology China Medical and Health Industry Co.
-
This JAK inhibitor imitation replacement is hot, the first imitation + the first over-review has fallen to Qilu's family
Time of Update: 2022-05-09
[Pharmaceutical Network Industry News] Recently, the State Food and Drug Administration's public information shows that Qilu Pharmaceutical's Tofacitinib Citrate Sustained-Release Tablets has been approved for marketing, becoming the first domestic imitation + first over-reviewed pharmaceutical company .
-
Strive to promote the development of the pharmaceutical industry, and formulate development plans to 2025 in many places
Time of Update: 2022-05-09
The "Implementation Plan for Accelerating the High-quality Development of the Biomedical Industry in Fujian Province" recently issued by Fujian proposes that by 2025, the province's pharmaceutical industry revenue will reach 120 billion yuan, and a number of leading backbone enterprises, key innovative products, technology research and development and Public service platform and characteristic industrial clusters .
-
Recently, a large number of pharmacies have been fined!
Time of Update: 2022-05-09
For example, recently, the State Food and Drug Administration announced five typical cases of special drug safety rectification, and a chain pharmacy was fined 1.
It is understood that the Drug Supervision Department of the State Food and Drug Administration has recently held a special inspection work conference on drug distribution and use .
-
More than 46 pharmaceutical companies announced their results for the first quarter. Who is happy and who is worried?
Time of Update: 2022-05-09
However, in the near future, there are still a number of pharmaceutical companies that have announced their report cards for the first quarter of 2022, including Livzon Group, Yuandong Bio, Hengrui Medicine, Asymchem, BGI, Pien Tze Huang, etc.
-
The rapid rise of the pharmaceutical industry in Chengdu, and the continuous major events
Time of Update: 2022-05-09
In 2022, Chengdu will promote the high-quality development of the industry, and it has set a clear goal: by 2025, it will cultivate two trillion-level, advanced manufacturing clusters in electronic information and equipment manufacturing, and create national advanced manufacturing industries such as aerospace, rail transit, and medicine and health.
-
Domestic pharmaceutical companies actively participate in the consistency evaluation of generic drugs, and there are many varieties that have been evaluated such as Yangzijiang and Qilu
Time of Update: 2022-05-09
In addition, the author was informed that on April 6, two generic drugs of Yangzijiang Pharmaceutical (Tedizolid Phosphate for Injection, Levetiracetam Tablets) were approved for marketing.
In addition, the author was informed that recently, the marketing applications of several first generic drugs of Qilu Pharmaceutical have been accepted .
-
In 2022, a large number of pharmaceutical companies will receive subsidies "red envelopes rain", and many will receive more than 100 million yuan
Time of Update: 2022-05-09
5 million in government subsidies related to income, accounting for 10% of the company's net profit attributable to shareholders of listed companies in the latest audited fiscal year.
-
Anti-infective drugs have made new progress in the challenge, and domestic pharmaceutical companies are actively deploying
Time of Update: 2022-05-09
It is reported that the listed companies in the domestic anti-infective drug industry include Puluo Pharmaceutical, Zhejiang Pharmaceutical, North China Pharmaceutical, and Jingxin Pharmaceutical .
Recently, Zhejiang Medicine issued an announcement that the anti-infective drug Linezolid Glucose Injection passed the consistency evaluation of generic drugs .
-
A large number of pharmaceutical companies released their first-quarter 2022 performance reports today
Time of Update: 2022-05-09
The company's shareholders' net profit after deducting non-recurring gains and losses was 378 million yuan, a year-on-year increase of 65.
Jiaying Pharmaceutical announced the report for the first quarter of 2022 that the company achieved operating income of 121 million yuan, a year-on-year decrease of 1.
-
Traditional Chinese medicine companies disclosed their first quarterly reports, and their performance soared
Time of Update: 2022-05-09
3%; net profit attributable to shareholders of listed companies was 689 million yuan, a year-on-year increase of 21.
93%; attributable to shareholders of listed companies The net profit after deducting non-recurring gains and losses was 676 million yuan, a year-on-year increase of 20.
